icon-folder.gif   Conference Reports for NaTaP  
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
  EASL: Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (05/05/15)
EASL: Derisking the Potential for Mitochondrial Toxicity of Nucleoside Analogs - (05/05/15)
EASL: Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis - (04/23/15)
EASL: On-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation (OLT): interim data from the Phase II SATURN study - (04/23/15)
EASL: Simeprevir plus daclatasvir and sofosbuvir in treatment-naïve and treatment-experienced patients with chronic hepatitis C virus genotype 1 or 4 infection and decompensated liver disease: interim results from the Phase II IMPACT study - (04/24/15)
EASL: A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2 - (04/29/15)
EASL: A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1 - (04/28/15)
COHORT Studies
EASL: All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET - (04/23/15)
EASL: Safety and Efficacy of Sofosbuvir-Containing Regimens in Hepatitis C Infected Patients with Reduced Renal Function: Real-World Experience from HCV-TARGET - (05/05/15)
EASL: Final evaluation of HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the TRIO network: academic and community treatment of a real-world, heterogeneous population - (04/30/15)
EASL: Comparison of sofosbuvir +/- simeprevir in heterogeneous, real-world populations of HCV patients over 70 years; data from the TRIO network - (04/30/15)
EASL: Real World Effectiveness and Cost of Simeprevir- and/or Sofosbuvir-based HCV Treatments - (04/28/15)
EASL: Safety and efficacy of all-oral DAA regimens in HIV-HCV coinfected cirrhotic patients from the prospective ANRS CO13 - HEPAVIH cohort - (04/28/15)